Physician profile
David Avram
NPI 1972598100
$15,861.90
in general payments reported to CMS, 2019-2025
33 companies · $881 in 2025
The $881 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $2,377 · 2021: $1,905 · 2022: $2,673 · 2023: $1,831 · 2024: $5,407 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,367 · Consulting Fee: $3,480 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,367.06 |
| Consulting Fee | $3,480.00 |
| Education | $271.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $4,562.53 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,336.41 | 2019-2025 | Siliq, Duobrii, Cabtreo |
| Janssen Biotech, INC. | $1,749.97 | 2020-2025 | Tremfya |
| Merz North America, INC. | $1,140.48 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $880.67 | 2019-2023 | |
| Abbvie INC. | $715.94 | 2020-2025 | Skyrizi |
| Sun Pharmaceutical Industries INC. | $652.05 | 2020-2025 | Winlevi |
| Pfizer INC. | $536.58 | 2021-2025 | |
| Lilly USA, LLC | $534.86 | 2019-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $481.78 | 2019-2025 | Epsolay, Twyneo, Oracea |
| Amgen INC. | $343.66 | 2020-2025 | Otezla |
| Ucb, INC. | $303.90 | 2021-2024 | Bimzelx, Cimzia |
| Allergan, INC. | $219.37 | 2019-2022 | |
| Genzyme Corporation | $206.19 | 2023-2025 | |
| Epi Health, LLC | $135.47 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $123.44 | 2021-2025 | Opzelura |
| Botanix Sb INC | $120.95 | 2025 | Sofdra |
| Mallinckrodt Hospital Products INC. | $119.97 | 2025 | Acthar |
| Mayne Pharma Commercial LLC | $118.09 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $100.41 | 2023-2024 | Zoryve |
| Vifor Pharma, INC. | $99.59 | 2022-2023 | Veltassa, Korsuva |
| Leo Pharma INC. | $79.70 | 2021-2025 | Anzupgo |
| Almirall LLC | $60.51 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $48.60 | 2023-2024 | Libtayo, Dupixent |
| Travere Therapeutics, INC. | $33.49 | 2023 | |
| Organogenesis INC. | $25.99 | 2025 | Puraply Wound Matrix |
| Organon LLC | $24.98 | 2025 | Vtama |
| Journey Medical Corporation | $20.58 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $20.00 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $19.73 | 2024 | |
| Aclaris Therapeutics, INC. | $17.85 | 2019 | |
| Merck Sharp & Dohme LLC | $16.44 | 2019 | |
| Strata Skin Sciences, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Avram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.